Zhengye Biotechnology Holding Ltd

Zhengye Biotechnology Holding Limited issued a statement in response to recent unusual trading activity in its Class A ordinary shares. The company confirmed it is not aware of any material non-public information, undisclosed corporate developments, transactions, or events that would account for the increase in trading volume and price. Zhengye Biotechnology stated its business operations continue in the ordinary course and is cooperating with Nasdaq and other regulatory authorities.

Zhengye Biotechnology Holding Limited issued a statement in response to recent unusual trading activity in its Class A ordinary shares. The company confirmed it is not aware of any material non-public information that would account for the increased trading activity, stating that business operations continue normally with no undisclosed corporate developments. Zhengye Biotechnology is cooperating with Nasdaq and other regulatory authorities and cautioned investors to rely on information in its SEC filings.

Zhengye Biotechnology Holding Limited announced it received a notice from Nasdaq on May 29, 2026, indicating non-compliance with the minimum bid price requirement. The company's Class A ordinary shares traded below $1.00 for 30 consecutive business days. Zhengye Biotechnology has a 180-calendar-day compliance period, until November 25, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days. The company's business operations are not affected, and its shares will continue to trade under the symbol "ZYBT" without immediate delisting.

Zhengye Biotechnology Holding Limited announced it received a written notification from Nasdaq on May 29, 2026, indicating non-compliance with the minimum bid price requirement of US$1.00 per share. The company's Class A ordinary shares traded below this threshold for 30 consecutive business days. Zhengye Biotechnology has 180 calendar days, until November 25, 2026, to regain compliance by maintaining a closing bid price of at least US$1.00 for a minimum of 10 consecutive business days. The company is monitoring the situation and may consider options such as a reverse share split, though its business operations are not currently impacted.